[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JOP20190101A1 - أنظمة علاج - Google Patents

أنظمة علاج

Info

Publication number
JOP20190101A1
JOP20190101A1 JOP/2019/0101A JOP20190101A JOP20190101A1 JO P20190101 A1 JOP20190101 A1 JO P20190101A1 JO P20190101 A JOP20190101 A JO P20190101A JO P20190101 A1 JOP20190101 A1 JO P20190101A1
Authority
JO
Jordan
Prior art keywords
treatment
prevention
treatment regimens
selectin
binding fragments
Prior art date
Application number
JOP/2019/0101A
Other languages
English (en)
Inventor
Andreas Bruederle
Jonathan Stocker
Russell Rother
Scott Rollins
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20190101A1 publication Critical patent/JOP20190101A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الاختراع الحالي بعلاج أو الوقاية من اضطرابات يتوسط فيها P-سيليكتين، وبالأجسام المضادة لـ P-سيليكتين أو شظايا ربط منها، للاستخدام في علاج أو الوقاية من هذه الاضطرابات. تحديدا، يتعلق الاختراع بعلاج أو الوقاية من حالات الألم المرتبطة بمرض الخلية المنجلية، وبالأجسام المضادة لـ P-سيليكتين أو شظايا ربط منها، للاستخدام في علاج أو الوقاية من حالات الألم المرتبطة بمرض الخلية المنجلية . الشكل 1/أ
JOP/2019/0101A 2016-11-03 2017-06-16 أنظمة علاج JOP20190101A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201618532 2016-11-03
US201762541133P 2017-08-04 2017-08-04

Publications (1)

Publication Number Publication Date
JOP20190101A1 true JOP20190101A1 (ar) 2019-05-05

Family

ID=60484413

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0101A JOP20190101A1 (ar) 2016-11-03 2017-06-16 أنظمة علاج

Country Status (11)

Country Link
US (1) US20240209097A1 (ar)
EP (1) EP3534946A1 (ar)
JP (1) JP2019534287A (ar)
AU (1) AU2017355613B2 (ar)
BR (1) BR112019008852A2 (ar)
CA (1) CA3040628A1 (ar)
IL (1) IL266292B2 (ar)
JO (1) JOP20190101A1 (ar)
SG (1) SG11201903106QA (ar)
TW (1) TW201819406A (ar)
WO (1) WO2018083645A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020326490A1 (en) * 2019-08-08 2022-03-24 Novartis Ag Use of the anti-P-selectin antibody crizanlizumab for treating sickle cell nephropathy and chronic kidney disease associated with sickle cell disease
US20220378912A1 (en) 2019-10-30 2022-12-01 Novartis Ag Crizanlizumab containing antibody formulations
WO2024206166A1 (en) * 2023-03-31 2024-10-03 Memorial Sloan-Kettering Cancer Center Microenvironment actuated t-cells and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2662091B1 (en) * 2006-12-01 2018-08-22 Selexys Pharmaceuticals Corporation Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases
AU2011349124B2 (en) * 2010-12-21 2016-09-15 Oklahoma Medical Research Foundation Anti-P-selectin antibodies and methods of their use and identification

Also Published As

Publication number Publication date
AU2017355613B2 (en) 2020-10-22
IL266292B2 (en) 2024-06-01
AU2017355613A1 (en) 2019-05-23
JP2019534287A (ja) 2019-11-28
IL266292A (en) 2019-06-30
WO2018083645A1 (en) 2018-05-11
IL266292B1 (en) 2024-02-01
BR112019008852A2 (pt) 2019-07-09
US20240209097A1 (en) 2024-06-27
SG11201903106QA (en) 2019-05-30
TW201819406A (zh) 2018-06-01
EP3534946A1 (en) 2019-09-11
CA3040628A1 (en) 2018-05-11

Similar Documents

Publication Publication Date Title
PH12018502429A1 (en) Antibody molecules for cancer treatment
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
PH12017500803A1 (en) Anti-pd-1 antibodies
JOP20200055A1 (ar) مركبات بيرازولو بيريميدينون واستخداماتها
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
MX2021009674A (es) Receptores de celulas t vgamma9vdelta2 humanas que se unen a inmunoglobulinas.
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
MY185813A (en) Factor xi antibodies and methods of use
MD20170035A2 (ro) Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
EA201400625A1 (ru) Антитела против pd-l1 и их применение
MX2016010953A (es) Proteinas de fc multimericas.
MX2015015249A (es) Peptidos terapeuticos.
MX2018014456A (es) Anticuerpos contra alfa-sinucleina y sus usos.
SA519402159B1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MY179105A (en) Methods of treating alzheimer's disease
MX2023007840A (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
MX2021005373A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
JOP20190101A1 (ar) أنظمة علاج